Subtype
Bile Duct Neoplasm
CI-CAN-00000563Explore in graph →
Non-malignant224 active trials3 approved drugs29 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000563Explore in graph →
Clinical trials
900 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05290116 | HAIC Combined With Tislelizumab and Apatinib for Unresectable Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 17 | Yunfei YuanOTHER | 1 | Aug 5, 2022 | clinicaltrials |
| NCT05464706 | Study on the Quality of Life (QoL) After Liver Surgery | completed | N/A | 60 | Humanitas Clinical and Research CenterOTHER | 1 | Aug 4, 2022 | clinicaltrials |
| NCT04717687 |
| Pilot Study on the Evaluation of Irreversible Electroporation Technique in Infiltrating Perihilar Cholangiocarcinoma(HOPE) |
| withdrawn |
| N/A |
| 0 |
| Poitiers University HospitalOTHER |
| 0 |
| Jul 13, 2022 |
| clinicaltrials |
| NCT04895046 | Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma | withdrawn | Phase 2 | 0 | Walid Shaib, MDOTHER | 0 | Jun 29, 2022 | clinicaltrials |
| NCT04637048 | Observational Study on Patients With Hepatobiliary Tumors | unknown | — | 1,000 | Gang Chen, MDOTHER | 1 | Jun 16, 2022 | clinicaltrials |
| NCT04546828 | A Single-arm Study of Gemcitabine, Cisplatin, and Nab-Paclitaxel as Neoadjuvant Therapy for Resectable Oncologically High-Risk IHCC in Korea | withdrawn | Phase 2 | 0 | Samsung Medical CenterOTHER | 0 | Jun 15, 2022 | clinicaltrials |
| NCT05418543 | CH-EUS in Diagnosis of Inoperable Bile Duct Tumors | unknown | N/A | 40 | Institutul Regional de Gastroenterologie & Hepatologie Prof. dr. Octavian FodorOTHER | 1 | Jun 15, 2022 | clinicaltrials |
| NCT02451553 | Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer | completed | Phase 1 | 41 | University of WashingtonOTHER | 1 | Jun 7, 2022 | clinicaltrials |
| NCT05402618 | Minimally Invasive Versus Open Surgery for PHC | completed | — | 783 | Renyi QinOTHER | 1 | Jun 2, 2022 | clinicaltrials |
| NCT04727541 | Neoadjuvant Bintrafusp Alfa in Patients With Resectable Biliary Tract Cancer(NEOBIL) | terminated | Phase 2 | 3 | AIO-Studien-gGmbHOTHER | 1 | May 23, 2022 | clinicaltrials |
| NCT03316222 | Study of GNS561 in Patients With Liver Cancer | terminated | Phase 1 / Phase 2 | 50 | Genoscience PharmaINDUSTRY | 3 | May 2, 2022 | clinicaltrials |
| NCT04316078 | A Novel Patient Engagement Platform Among Patients With Gastrointestinal Malignancies | completed | N/A | 126 | Sheba Medical CenterOTHER_GOV | 1 | Apr 28, 2022 | clinicaltrials |
| NCT04480190 | Neoadjuvant Therapy in Biliary Adenocarcinoma | withdrawn | Phase 1 | 0 | Jordan KharofaOTHER | 1 | Apr 20, 2022 | clinicaltrials |
| NCT05327907 | Establishment of Scoring Model for Early and Differential Diagnosis of Intrahepatic Cholangiocarcinoma | unknown | — | 300 | Qilu Hospital of Shandong UniversityOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT05320328 | RADIO FREQUENCY ABLATION IN UNRESECTABLE MALIGNANT BILIARY OBSTRUCTION(MBOP) | unknown | — | 50 | Asian Institute of Gastroenterology, IndiaOTHER | 1 | Apr 11, 2022 | clinicaltrials |
| NCT03852836 | Evaluation of MRI Sequences for Ultra-rapid Acquisition of Bile Ducts Images(BiliFast) | terminated | N/A | 53 | IHU StrasbourgOTHER | 1 | Apr 6, 2022 | clinicaltrials |
| NCT04946773 | Deep Liver Phenotyping and Immunology Study(DELPHI) | recruiting | — | 100 | University of OxfordOTHER | 1 | Apr 6, 2022 | clinicaltrials |
| NCT05019677 | GP Chemotherapy in Combination With Tislelizumab and Ociperlimab as First-line Treatment in Advanced BTC | withdrawn | Phase 2 | 0 | Fudan UniversityOTHER | 1 | Apr 4, 2022 | clinicaltrials |
| NCT03086993 | Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma | unknown | Phase 2 / Phase 3 | 295 | Delcath Systems Inc.INDUSTRY | 1 | Mar 24, 2022 | clinicaltrials |
| NCT04611100 | Efficacy of Intraductal Radiofrequency Ablation in Combination With Metallic Biliary Stenting in Advanced Hilar Cholangiocarcinoma | completed | N/A | 70 | Department of Medical Services Ministry of Public Health of ThailandOTHER_GOV | 1 | Mar 23, 2022 | clinicaltrials |
| NCT02591030 | Safety and Efficacy of Modified Folfirinox Versus Gemcis in Bile Duct Tumours(AMEBICA) | completed | Phase 2 / Phase 3 | 191 | Centre Hospitalier Universitaire de Saint EtienneOTHER | 1 | Feb 24, 2022 | clinicaltrials |
| NCT04648319 | A Study of BMS-936558 With SBRT After Induction Chemotherapy in Cholangiocarcinoma | terminated | Phase 2 | 1 | American University of Beirut Medical CenterOTHER | 3 | Feb 23, 2022 | clinicaltrials |
| NCT05251662 | Sintilimab Combined With GEMOX ± IBI305 (Bevacizumab Biosimilar) Versus GEMOX in Advanced Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 90 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 23, 2022 | clinicaltrials |
| NCT04847167 | Mechanistic Loop Resolution Strategy for Short-type Single Balloon Enteroscopy | completed | N/A | 23 | Ajou University School of MedicineOTHER | 1 | Feb 21, 2022 | clinicaltrials |
| NCT05247996 | TACE Combined With "Target Immune" Therapy for First-line Treatment in the Treatment of Intrahepatic Cholangiocarcinoma | unknown | N/A | 98 | The Central Hospital of Lishui CityOTHER | 0 | Feb 21, 2022 | clinicaltrials |
| NCT02982720 | Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron | terminated | Phase 2 | 4 | Aiwu Ruth He, MDOTHER | 1 | Feb 16, 2022 | clinicaltrials |
| NCT02392637 | Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel in Treating Patients With Advanced or Metastatic Biliary Cancers | completed | Phase 2 | 62 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 2, 2022 | clinicaltrials |
| NCT05207735 | PD-1 Inhibitor Sintilimab Combined With Capecitabine for Adjuvant Treatment After Radical Resection of Cholangiocarcinoma.(SCRCA) | unknown | Phase 2 | 73 | Henan Cancer HospitalOTHER_GOV | 0 | Jan 26, 2022 | clinicaltrials |
| NCT05184400 | Identification of New Biomarkers for Patients With Cholangiocarcinoma and Gallbladder Cancer(CHOCA) | recruiting | — | 500 | Herlev and Gentofte HospitalOTHER | 1 | Jan 11, 2022 | clinicaltrials |
| NCT05155878 | Prognostic Factors in Periampullary Tumors and Cysts | recruiting | — | 500 | Umeå UniversityOTHER | 1 | Jan 5, 2022 | clinicaltrials |
| NCT05172310 | PET Imaging of Solid Tumors by a Novel Tracer, 68Ga-FAPI | recruiting | Phase 1 | 410 | Karolinska University HospitalOTHER | 1 | Dec 29, 2021 | clinicaltrials |
| NCT03796819 | Routine Lymphadenectomy for Intrahepatic Cholangiocarcinoma(LND for ICC) | completed | N/A | 260 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Dec 9, 2021 | clinicaltrials |
| NCT05148143 | RALOX as Second Line Treatment for Advanced Malignant Biliary System Tumor(RALOXBTC) | unknown | Phase 2 | 50 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Dec 8, 2021 | clinicaltrials |
| NCT03111732 | Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC) | completed | Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | Dec 3, 2021 | clinicaltrials |
| NCT04937322 | Radio Frequency Ablation in the Management of Pancreatico-biliary Disorders: A Multicenter Registry. | completed | — | 8 | Methodist Health SystemOTHER | 1 | Nov 11, 2021 | clinicaltrials |
| NCT02232932 | Liver Resection Versus Radio-chemotherapy-Transplantation for Hilar Cholangiocarcinoma(TRANSPHIL) | unknown | N/A | 60 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Nov 3, 2021 | clinicaltrials |
| NCT03486678 | SHR-1210 in Combination With GEMOX in Patients With Advanced BTC | completed | Phase 2 | 38 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Oct 28, 2021 | clinicaltrials |
| NCT02128282 | Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma | completed | Phase 1 / Phase 2 | 127 | Senhwa Biosciences, Inc.INDUSTRY | 3 | Oct 22, 2021 | clinicaltrials |
| NCT03644173 | Personal Resilience Empowerment Program Study | completed | N/A | 37 | Hackensack Meridian HealthOTHER | 1 | Oct 15, 2021 | clinicaltrials |
| NCT02115542 | Single Agent Regorafenib in Refractory Advanced Biliary Cancers | completed | Phase 2 | 39 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Oct 12, 2021 | clinicaltrials |
| NCT03041662 | Surveillance Study for Early Detection of Cholangiocarcinoma (CCA) in Primary Sclerosing Cholangitis (PSC)(PSC) | completed | — | 620 | Karolinska University HospitalOTHER | 1 | Sep 16, 2021 | clinicaltrials |
| NCT03603834 | Neoadjuvant mFOLFOXIRI for Potentially Resectable Cholangiocarcinoma | unknown | Phase 2 | 25 | Khon Kaen UniversityOTHER | 1 | Sep 1, 2021 | clinicaltrials |
| NCT04301999 | Clinical Effect and Safety of PDT and RFA for Unresectable EHCC | completed | N/A | 67 | First People's Hospital of HangzhouOTHER | 1 | Sep 1, 2021 | clinicaltrials |
| NCT02631590 | Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma | completed | Phase 2 | 24 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Aug 4, 2021 | clinicaltrials |
| NCT04337333 | Two-in-one Covered and Uncovered Metal Stent | unknown | N/A | 100 | Ajou University School of MedicineOTHER | 1 | Jul 21, 2021 | clinicaltrials |
| NCT04511793 | Hepatic Artery Infusion (HAI) Program at Duke University | withdrawn | N/A | 0 | Michael Lidsky, M.D.OTHER | 0 | Jul 19, 2021 | clinicaltrials |
| NCT04779788 | I-125 Seeds Loaded Stent Insertion for Inoperable Hilar Cholangiocarcinoma | unknown | N/A | 100 | Xuzhou Central HospitalOTHER | 1 | Jul 14, 2021 | clinicaltrials |
| NCT04961788 | Anti-PD1 Antibody Toripalimab Combined With Gemox as First-line Therapy in Late-stage Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 30 | Shanghai Zhongshan HospitalOTHER | 1 | Jul 14, 2021 | clinicaltrials |
| NCT04961970 | HAIC With FOLFOX Versus Systemic Chemotherapy With GP for Unresectable ICC | unknown | Phase 3 | 188 | Shi MingOTHER | 1 | Jul 14, 2021 | clinicaltrials |
Data updated 24 days agoSource updated Aug 5, 2022source: clinicaltrials